Background

Acute postoperative pain remains a significant clinical challenge. Opioid analgesics, though effective, are associated with adverse effects such as respiratory depression, constipation, nausea, and the risk of dependence. Non-opioid agents like NSAIDs and acetaminophen offer safer alternatives but often provide only modest relief in moderate to severe pain.

Suzetrigine (Journavx), developed by Vertex Pharmaceuticals, is a first-in-class, orally administered small-molecule inhibitor of the voltage-gated sodium channel subtype NaV1.8. This channel is selectively expressed in peripheral nociceptive neurons and not in the brain or spinal cord, allowing for targeted pain relief without CNS-mediated side effects or addiction potential.

Mechanism of Action

NaV1.8 is primarily expressed in the peripheral sensory neurons responsible for transmitting pain signals. Because it is not expressed in the brain or spinal cord, selective inhibition of NaV1.8 provides a novel approach to analgesia without the sedative or addictive effects common with centrally acting agents.

Suzetrigine binds selectively to NaV1.8 channels, reducing nociceptor excitability and blocking propagation of pain impulses from the periphery to the CNS. Through this peripheral mechanism, suzetrigine offers the potential for effective pain relief while avoiding opioid-related adverse effects and misuse potential.

Drug-Drug Interactions and Dose Adjustments

Suzetrigine is primarily metabolized by CYP3A. Concomitant use with moderate or strong CYP3A inhibitors, such as itraconazole or clarithromycin, may increase suzetrigine exposure, whereas coadministration with CYP3A inducers, including rifampin or carbamazepine, may decrease plasma concentrations and reduce efficacy. Caution is advised when suzetrigine is used with these agents, and clinicians should consider dosage adjustments or close monitoring for changes in efficacy or adverse effects. In patients with moderate hepatic impairment (Child-Pugh class B), the AUC increases by around 1.5-fold; however, use has not been studied in severe hepatic impairment (Child-Pugh class C). According to available data, no clinically meaningful renal dose adjustment appears necessary.

Clinical Indications

Suzetrigine is indicated for the treatment of moderate to severe acute postoperative pain in adults when alternative non-opioid treatments are inadequate. It is administered orally as a 100-mg loading dose, followed by 50 mg every 12 hours for the shortest duration with patient treatment goals; use beyond 14 days has not been studied.

Clinical Evidence

Two phase 3 randomized controlled trials evaluated the efficacy and safety of suzetrigine in adults with moderate to severe acute pain after abdominoplasty (soft-tissue model) and bunionectomy (hard-tissue model). Participants were randomized to receive suzetrigine, hydrocodone-acetaminophen, or placebo over a 48-hour period.

Suzetrigine demonstrated a statistically significant reduction in pain intensity versus placebo in both trials (abdominoplasty: least-squares mean difference, 48.4; P < .0001; bunionectomy: 29.3; P = .0002). Although suzetrigine did not meet superiority criteria compared with hydrocodone-acetaminophen, its analgesic efficacy was similar.

Adverse events were generally mild or moderate, with nausea, constipation, dizziness, and headache being the most common. Of importance, rates of nausea and vomiting were lower with suzetrigine than with the opioid comparator, and no treatment-related serious adverse events were reported.

Clinical Implications

Suzetrigine represents a novel mechanism for acute pain management, offering analgesia through selective NaV1.8 inhibition without the risks associated with opioids. Its similar efficacy and improved tolerability profile support its potential role as a component of multimodal postoperative pain regimens.

Further research should evaluate its performance against commonly used postoperative analgesics, such as oxycodone combinations and gabapentin, to determine its suitability for broader use in moderate to severe pain. Long-term safety and effectiveness in real-world surgical populations also warrant continued study.

References

1. Bertoch T, D’Aunno D, McCoun J, et al. Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology. 2025;142(6):1085-1099. https://doi.org/10.1097/ALN.0000000000005460

2. Bozic C, Weiner SG, Negulescu P, et al. Supplemental digital content: clinical data tables and statistical analysis plan. Anesthesiology. 2025. Accessed June 3, 2026. https://cdn-links.lww.com/permalink/aln/d/aln_2025_03_17_bozic_aln-d-24-01394_sdc1.pdf

3. Osteen JD, Immani S, Tapley TL, et al. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther. 2025;14(2):655-674. https://doi.org/10.1007/s40122-024-00697-0

4. US Food and Drug Administration. FDA approves novel non-opioid treatment for moderate-to-severe acute pain. Press release. March 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain

5. Vertex Pharmaceuticals. Journavx (suzetrigine) mechanism of action. Healthcare Professional Website. https://www.journavxhcp.com/mechanism-of-action